Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.54 |
| ▸ | ACR | P10323 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.54 |
| ▸ | BCL9 | O00512 | 1/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5696807 | 1.00 | KMT2A (0.72) | KMT2APKMHGFACMEN1NR1H4 | |
| SCHEMBL2597339 | 1.00 | KMT2A (0.72) | KMT2APKMHGFACMEN1NR1H4 | |
| SCHEMBL18434657 | 0.92 | KMT2A (0.84) | KMT2APKMHGFACNR1H4MAPT | |
| SCHEMBL542043 | 0.92 | KMT2A (0.84) | KMT2APKMHGFACNR1H4MAPT | |
| SCHEMBL10636579 | 0.92 | KMT2A (0.84) | KMT2APKMHGFACNR1H4MAPT | |
| SCHEMBL4951809 | 0.92 | KMT2A (0.84) | KMT2APKMHGFACNR1H4MAPT | |
| SCHEMBL7796532 | 0.92 | HGFAC (0.66) | KMT2APKMHGFACMEN1NR1H4 | |
| SCHEMBL23918341 | 0.88 | MAOB (0.68) | KMT2APKMHGFACMEN1MAPT | |
| SCHEMBL6986709 | 0.87 | KMT2A (0.72) | KMT2APKMHGFACMEN1NR1H4 | |
| SCHEMBL5345292 | 0.87 | KMT2A (0.72) | KMT2APKMHGFACMEN1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210349035-A1 | PATHOGEN MONITORING | PLATYPUS TECHNOLOGIES, LLC | 2021-11-11 | — | — | US | disclosed |
| US-10928306-B2 | Functional surfaces for liquid crystal-based detection of chlorine gas | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190212254-A1 | Functional Surfaces for Liquid Crystal-Based Detection of Chlorine Gas | NATIONAL SCIENCE FOUNDATION | 2019-07-11 | — | — | US | disclosed |
| US-20180052111-A1 | SUBSTRATES, DEVICES, AND METHODS FOR QUANTITATIVE LIQUID CRYSTAL ASSAYS | PLATYPUS TECHNOLOGIES, LLC | 2018-02-22 | — | — | US | disclosed |
| US-9816147-B2 | Liquid crystal based analyte detection | PLATYPUS TECHNOLOGIES, LLC (US) | 2017-11-14 | — | — | US | disclosed |
| US-9797843-B2 | Substrates, devices, and methods for quantitative liquid crystal assays | PLATYPUS TECHNOLOGIES, LLC (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170212088-A1 | DETECTION OF GAS-PHASE ANALYTES USING LIQUID CRYSTALS | PLATYPUS TECHNOLOGIES, LLC | 2017-07-27 | — | — | US | disclosed |
| US-9575037-B2 | Detection of gas-phase analytes using liquid crystals | PLATYPUS TECHNOLOGIES, LLC (US) | 2017-02-21 | — | — | US | disclosed |
| US-8133680-B2 | affinity substrate comprises polydimethylsiloxane stamp alternately peptide-terminated or antibody terminated; | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-03-13 | — | — | US | disclosed |
| US-7662572-B2 | Compositions and liquid crystals | PLATYPUS TECHNOLOGIES, LLC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-7651662-B2 | Rubbed substrate surfaces; activation; uniform anchoring of liquid crystals | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-20070099249-A1 | Compositions and liquid crystals | PLATYPUS TECHNOLOGIES, LLC (US) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099249-A1 | Compositions and liquid crystals | FABP5, FABP1, SSB | KMT2A 4615/4885PKM 1801/4885HGFAC 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.